Patents by Inventor Patricia McNeeley

Patricia McNeeley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
    Patent number: 11999789
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: June 4, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., CEDARS-SINAI MEDICAL CENTER
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A
    Publication number: 20230272098
    Abstract: Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A. Also provided are methods, systems and kits for detecting the one or more genotypes described herein.
    Type: Application
    Filed: May 12, 2023
    Publication date: August 31, 2023
    Inventors: Laurens KRUIDENIER, Mahyar SABRIPOUR, Jeffry D. Watkins, Cindy T. DICKERSON, Rafael ROJAS, Matthew REISSMAN, Patricia MCNEELEY, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20230192835
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: September 9, 2022
    Publication date: June 22, 2023
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Optimized anti-TL1A antibodies
    Patent number: 11440954
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20220259320
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 28, 2022
    Publication date: August 18, 2022
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
    Patent number: 11292848
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 5, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20210122828
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: December 2, 2020
    Publication date: April 29, 2021
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20210070871
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: April 24, 2019
    Publication date: March 11, 2021
    Inventors: Jeffry D. WATKINS, Cindy T. DICKERSON, J. Monty WATKINS, Patricia MCNEELEY
  • METHODS AND COMPOSITIONS FOR DIFFERENTIAL EXPANSION OF FETAL CELLS IN MATERNAL BLOOD AND THEIR USE
    Publication number: 20110039258
    Abstract: Disclosed is a method and compositions for the differential expansion of fetal cells over maternal cells. In the method, cells from a sample of maternal blood containing CD34+ cells of both maternal and fetal origin are incubated in the presence of Stem Cell Factor in serum free media. It has been discovered that incubation of fetal cells in the presence of SCF will preferentially expand the fetal cells relative to adult cells. Fetal cells can also be identified, enriched or obtained by differential expansion of the fetal cells during colony formation. It has been discovered that differential expansion of fetal cells can result in colonies of fetal cells that are larger than colonies of adult cells. The fetal CD34+ cells can be expanded without generation of significant clonal genetic artifacts during expansion. Also disclosed is a method and compositions for producing differentiated fetal cells.
    Type: Application
    Filed: October 15, 2007
    Publication date: February 17, 2011
    Applicant: CELULA INC.
    Inventors: Patricia McNeeley, Philippe Marchand, Jonathan Diver
  • Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
    Patent number: 7081242
    Abstract: The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 25, 2006
    Assignee: La Jolla Pharmaceutical Company
    Inventors: Matthew D. Linnik, Patricia A. McNeeley
  • Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
    Publication number: 20060142229
    Abstract: The invention provides methods identifying individuals suitable for treatment for lupus and methods of monitoring treatment, based on measuring antibody affinities, as well as of treating lupus based on measuring antibody affinities. The treatment entails administration of a conjugate comprising a non-immunogenic valency platform molecule and at least two double stranded DNA epitopes, such as DNA molecules, which bind to anti-DNA antibodies from the patient.
    Type: Application
    Filed: March 15, 2005
    Publication date: June 29, 2006
    Applicant: La Jolla Pharmaceutical Company
    Inventors: Matthew Linnik, Patricia McNeeley